Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-020-00899-x
Keywords
Acute myeloid leukemia; Mesenchymal stem cells; Mesenchymal cancer stem cells; CD44; Angiogenesis; Microenvironment
Categories
Funding
- Loma Linda University Research Innovation Grant
- LLU GRASP
Ask authors/readers for more resources
Here, we report a unique acute myeloid leukemia (AML) bone marrow-derived mesenchymal stem cell (MSC) with both mesenchymal and endothelial potential, which we have named Mesenchymal Cancer Stem Cells (MCSCs). These MCSCs are CD90-CD13-CD44+ and differ from MSCs in isolation, expansion, differentiation, immunophenotype, and cytokine release profile. Furthermore, blocking CD44 inhibited the proliferation and cluster formation of early MCSCs with lower ICAM-1 protein levels. Similar CD90-CD44+ cancer stem cells have been reported in both gastric and breast cancers, which grew in floating spheres in vitro and exhibited mesenchymal features and high metastatic/tumorigenic capabilities in vivo. Our novel discovery provides the first evidence that certain AMLs may be comprised of both hematopoietic and stromal malignant cells. Targeting MCSCs and their cytokine release has potential as a novel therapeutic approach in AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available